iBET is a private non-profit research and development institute that uniquely converges engineering and biology to foster innovation in biopharmaceuticals. With a strong mission to enhance the development of new biopharmaceutical products, iBET offers cutting-edge solutions in areas such as bioengineering, gene therapy, and protein biophysics. The institute boasts over 50 state-of-the-art laboratories dedicated to advancing cell-based therapies, drug discovery, and immunology research.

iBET is heavily involved in impactful projects, including the development of next-generation vaccines and advanced cell models for testing groundbreaking therapies. Their commitment to fostering scientific collaboration is evident through partnerships with both academic institutions and industry leaders, culminating in over 270 dedicated employees and numerous ongoing R&D projects.

Moreover, iBET emphasizes knowledge transfer and career development, offering excellent training for early-career scientists through initiatives like the iBETXplore program. With a robust portfolio of publications and a commitment to innovation, iBET is shaping the future of biotechnology globally.